Introduced by: New York

Subject: Payment for Brand Medications When the Generic Medication is Recalled

Referred to: Reference Committee A
(John Montgomery, MD, Chair)

Whereas, There have been many generic medication recalls recently in the United States because of poor manufacturing processes and oversight by the US Food and Drug Administration; and

Whereas, These recalls have resulted in medication shortages and have placed patients at risk; and

Whereas, Insurance companies and government programs will not pay for the brand medication that has not been recalled at the generic tier; and

Whereas, The Pharmacy Benefit Plans will not cover these medications, leaving a treatment and financial gap for patients; therefore be it

RESOLVED, That our American Medical Association petition the Centers for Medicare and Medicaid Services as well as third party payers to allow reimbursement for brand medications at the lowest copayment tier so that patients can be effectively treated until the medication manufacturing crisis is resolved. (Directive to Take Action)

Fiscal Note: Not yet determined

Received: 04/25/19